Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

Kenvue (KVUE) could really use some good news. The Johnson & Johnson (JNJ) spinoff faced longlasting troubles regarding its talc-based baby powder products, including allegations that they caused cancer and related lawsuits. Now, the consumer health giant faces new troubles as President Donald Trump has accused its Tylenol product of increasing autism when used in pregnancy. More News from Barchart However, Kenvue is not backing off and taking the accusations head-on. In a submission to the Food and Dru ...